During the Annual Meeting’s third clinical trials plenary session, researchers reported promising results from four early-phase trials. Samer A. Srour, MD, reported results from the first-in-human trial of allogeneic CAR T therapy targeting CD70 expressed in metastatic renal cell carcinoma.

In the final clinical trials plenary session of the Annual Meeting, researchers highlighted more promising studies. Jordi Rodon, MD, PhD, reported results from the FIGHT-207 trial of pemigatinib, which showed antitumor activity in multiple pretreated solid tumors with FGFR alterations.

Annual Meeting Program Committee Chair Robert H. Vonderheide, MD, DPhil, shares a few highlights from Wednesday’s schedule to help plan your day.

To mark the 25th anniversary of trastuzumab, H. Michael Shepard, PhD, and three other scientists who were involved in the discoveries that led to the development of the drug discussed how those discoveries continue to inform cancer care and research.

During a Tuesday morning plenary session, Miriam Merad, MD, PhD, and a panel of cancer immunologists discussed some of the latest discoveries that are driving advances in cancer immunology research and therapeutic development.

During a Monday symposium, three researchers, including Quynh-Thu Le, MD, explored the potential of novel strategies to enhance the efficacy of radiation therapy in solid cancer at the individual level, and how these emerging therapies could help clinicians address the challenge of predicting therapeutic response.